Bio-Techne launches multiplex spatial genomics assay

By Samantha Black, PhD, contributing writer

July 27, 2021 -- Bio-Techne has expanded its Advanced Cell Diagnostics brand's RNAscope in situ hybridization technology portfolio with the release of the new RNAscope HiPlex V2 assay for formalin-fixed, paraffin-embedded (FFPE) and fixed and frozen samples for up to 12 targets.

The RNAscope HiPlex V2 assay is designed to enable a deeper understanding of gene expression patterns at a single-cell resolution. The assay can generate precision expression data from 12 targets in FFPE samples and up to 48 targets in fresh and fixed frozen samples, according to the company.

The new RNAscope HiPlex V2 assay can profile different cell types within the tumor microenvironment.
The new RNAscope HiPlex V2 assay can profile different cell types within the tumor microenvironment. Twelve target-specific marker probes were used to detect immune cells, tumor cells, chemokines, and cytokines in lung cancer. Image courtesy of Advanced Cell Diagnostics.

The assay also allows for direct visualization of the transcript and eliminates the need for bioinformatics methods for analysis and interpretation of single-cell RNA sequencing data. The multiplexed assay can be performed on commonly available laboratory equipment and is customizable with Bio-Techne's catalog of RNAscope probes or custom probes for any target.

Intended for research use only, the new release positions the company to better support the rapidly growing field of spatial genomics.

Bio-Techne teams up with Leica to bring RNAscope to Europe
Global life sciences firm Bio-Techne and pathology workflow software developer Leica Biosystems have launched Bio-Techne's RNAscope in situ hybridization...
Bio-Techne's prostate cancer test lands FDA breakthrough status
Bio-Techne's ExoDx Prostate IntelliScore liquid biopsy test for spotting aggressive prostate cancers has received the U.S. Food and Drug Administration's...

Copyright © 2021

Last Updated np 9/1/2021 12:18:14 PM